By Jacob Gronholt-Pedersen and Maggie Fick COPENHAGEN/LONDON (Reuters) -Years before Novo Nordisk's obesity drug Wegovy ...

It was a ‘mutual agreement,’ Novo says in a statement. A search for Fruergaard Jørgensen’s successor is ongoing.

Novo Nordisk A/S' CEO transition sparks governance concerns, but internal succession ensures stability. Click for my updated ...

The company behind the weight loss sensation that transformed bodies and bank accounts across America just showed its own CEO ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Polen Capital, an investment management company, released its “Polen Focus Growth Strategy” first quarter 20245 investor ...

Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing ...

Novo Nordisk CEO Lars Jørgensen to step down amid increasing pressure from obesity drug competition and recent share price ...

Novo Nordisk (NVO) stock fell after announcing that CEO Lars Fruergaard Jørgensen will step down. BMO Capital Markets ...

Bundled Offer Includes Wegovy® at $199 and LifeMD’s Virtual Weight Loss Program for a Total First-Month Cost of $299, $599 per Month Thereafter ...

Novo Nordisk chair Helge Lund on Friday said the company's strategy is unchanged despite the shake-up. Lund said last week the search would include internal and external candidates and Jorgensen ...

The future is powered by artificial intelligence ... In its first-quarter 2025 investor letter, Polen Focus Growth Strategy highlighted stocks such as Novo Nordisk A/S (NYSE:NVO).